The European Medicines Agency said Eli Lilly and Co. and Amylin Pharmaceuticals' once-weekly injectable Bydureon is suitable for adults with type 2 diabetes. Bydureon, a potential rival to Novo Nordisk's once-daily treatment Victoza, was rejected by the FDA last year. "While we believe the EU decision is completely separate from the FDA's decision ... we believe the EU's decision suggests they view Bydureon safe enough for use and the U.S. may likely follow," wrote analyst Robyn Karnauskas of Deutsche Bank.

Full Story:

Related Summaries